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ABSTRACT: Lysosomes perform a critical cellular function
as a site of degradation for diverse cargoes including proteins,
organelles, and pathogens delivered through distinct pathways,
and defects in lysosomal function have been implicated in a
number of diseases. Recent studies have elucidated roles for
the lysosome in the regulation of protein synthesis,
metabolism, membrane integrity, and other processes involved
in homeostasis. Complex small-molecule natural products have
greatly contributed to the investigation of lysosomal function
in cellular physiology. Here we report the discovery of a novel,
small-molecule modulator of lysosomal acidiﬁcation derived
from diversity-oriented synthesis through high-content screen-
ing.
■ INTRODUCTION
Studies of human genetics and physiology have implicated
autophagy in several inﬂammatory, neurodegenerative, infec-
tious, and autoimmune diseases, revealing the importance of
cellular homeostasis in human disease and motivating the
discovery of small-molecule probes to investigate the diﬀerent
stages of this complex pathway.1−3 Lysosomes are the site of
degradation and recycling in eukaryotic cells for macro-
molecules, organelles, and pathogens engulfed through
autophagy, endocytosis, and phagocytosis. Degradation within
the lysosome is facilitated by lysosomal hydrolases, including
proteases, peptidases, phosphatases, nucleases, glycosidases,
and lipases, and products are released by diﬀusion or carrier-
mediated transporters for reuse by cells.4 In some cell types,
lysosomes can also deliver cargo to pathogen recognition
receptors (PRRs), or preserve degraded cargo for antigen
presentation.5 The acidic pH in the lysosomal lumen (pH =
4.5−5.0), which is required for optimal hydrolase activity, is
generated and maintained by the vacuolar-type H+-ATPase (V-
ATPase), a protein complex on lysosomal membranes that
hydrolyzes ATP to drive protons into lysosomes.6 Mutations in
various subunits of the V-ATPase complex have been linked to
osteopetrosis,7,8 x-linked myopathy,9 distal renal tubular
acidosis, sensorineural deafness,10,11 and pulmonary tuber-
culosis,12 and the complex has been studied as a potential
dependency of certain cancer cells.6,13,14
Beyond its degradative function, recent studies have
identiﬁed the lysosome as a critical component of various
signaling pathways. For example, amino acids in the lysosomal
lumen promote the recruitment of the mechanistic target of
rapamycin (mTOR) to the lysosomal membrane and the
activation of mTOR signaling in a V-ATPase- and ragulator-
dependent manner,15,16 leading to enhancement of cell growth
and protein synthesis and inhibition of autophagy.17 mTOR
also regulates TFEB, a transcription factor that promotes
expression of genes required for the biogenesis of lysosomes
and activation of the endolysosomal system and autophagic
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catabolism.18,19 Lysosomes and lysosomal proteins, such as
Niemann-Pick disease C1 (NPC1) and NPC2, additionally
maintain cholesterol homeostasis by controlling cholesterol
eﬄux from the lysosomal lumen.20,21 The lysosome is also
involved in exocytosis to promote intercellular signaling and
plasma membrane repair through fusion with the plasma
membrane to restore membrane integrity.22
The study of lysosomes has been greatly enabled by the
discovery of small-molecule probes that perturb lysosomal
function through distinct mechanisms, including direct
inhibition of lysosomal proteases, inhibition of the V-ATPase,
extrusion and degradation of enzymes from the lysosomal
membrane, or perturbation of lysosomal pH through
protonation and accumulation in lysosomes.23,24 Many of
these modulators are derived from natural sources, including
the protease inhibitors leupeptin, pepstatin A, and E64d, as well
as several classes of V-ATPase modulators, including the
plecomacrolides, baﬁlomycin A1 and concanamycin A; the
macrolides, archazolid A and palmerolide A; and the
benzolactone enamides, apicularen A and salicylihalamide
A.25,26 Additional small molecules that perturb the lysosome
may serve as useful tools to study its role in cellular physiology
and human disease biology.
Diversity-oriented synthesis (DOS) aims to synthesize
candidate probes and therapeutics having novel mechanisms
of action not easily found in other sources of synthetic
compounds. The short and modular synthetic pathways that
result from the build/couple/pair (BCP) strategy, which
mimics the strategy used in nature to synthesize natural
products, ensure ease of chemical optimization of starting
points found using screening. This chemistry has yielded
compounds enriched for sp3-hybridized skeletal atoms and
often results in all possible stereoisomers to maximize diversity
of scaﬀold shape.27−30
Here we report the discovery of a novel small-molecule
inhibitor of lysosomal acidiﬁcation (BRD1240) through high-
content screening of a DOS-derived compound collection. We
identiﬁed BRD1240 on the basis of its ability to increase
numbers of autophagosomes, as measured by GFP-LC3
punctae accumulation. Among screening hits, BRD1240
displayed a particularly striking dependence of activity on
stereochemistry, suggesting a potentially selective interaction
with a protein target. Subsequent experiments revealed that
BRD1240 blocks the maturation of autophagosomes to
autolysosomes, likely due to its ability to interfere with
lysosomal acidiﬁcation.
To study the mechanism of action of BRD1240, we
measured the sensitivity of 83 cancer cell lines to BRD1240
and compared the resulting sensitivity proﬁle to those of 480
other small molecules spanning a range of protein targets; the
proﬁle of BRD1240 correlated most strongly with that of
baﬁlomycin A1, a potent, speciﬁc inhibitor of the V-ATPase.
Biochemical assays conﬁrmed that BRD1240 can suppress V-
ATPase function, though with kinetics diﬀerent than that of
baﬁlomycin A1, suggesting it may operate through a diﬀerent
molecular mode of action. BRD1240 may serve as a probe to
study how lysosomal acidiﬁcation is regulated by the multi-
subunit molecular machine, V-ATPase, and how it aﬀects
cellular physiology.
■ RESULTS AND DISCUSSION
BRD1240 Increases Autophagosome Number by
Inhibiting Autophagosomal Turnover. We performed a
high-throughput screen (HTS) of 59 541 stereochemically and
skeletally diverse compounds derived from DOS for com-
pounds that modulate autophagosome number. The primary
HTS was conducted in HeLa cells stably expressing a GFP-LC3
fusion protein (Figure 1). LC3 normally displays a diﬀuse
cytosolic pattern (LC3-I), but upon induction of autophagy,
LC3 is cleaved and conjugated to phosphatidylethanolamine
(LC3-II), and accumulates on autophagosome membranes. As
such, the number of autophagosomes can be estimated by
counting the number of GFP-LC3 “punctae/cell” by micros-
copy.31 Hits were selected on the basis of their ability to elicit
statistically signiﬁcant changes in the number of punctae/cell
compared with the observed number in DMSO-treated wells.
Signiﬁcance was assessed by computing the area under the
curve of the test distribution in compound-treated wells beyond
the critical value corresponding to 95% conﬁdence of the null
distribution estimated from the observed number of “punctae/
cell” in DMSO-treated wells.
Among conﬁrmed hits, BRD1240 was particularly potent and
displayed a striking structure−activity relationship (SAR) with
respect to the stereochemistry within the ring (Figure 1). Only
two of the eight stereoisomers were active, the SSS and RSS
diastereomers, with the sole diﬀerence being the conﬁguration
of the extra-annular methyl group; all other stereoisomers were
inactive (Figure 1C,D and Supporting Information Figure S1).
The dependence of BRD1240 activity on its stereochemistry
suggests a small-molecule−protein interaction that is highly
Figure 1. BRD1240 increases the GFP-LC3 punctae number, and this
activity is dependent on stereochemistry. (A) Chemical structure of
BRD1240. (B) Dose−response curves of BRD1240 (SSS) and
BRD8705 (RSS) in the GFP-LC3 punctae formation assay. The
positive control for increased punctae number is PI-103, a dual PI3K/
mTOR inhibitor. Values are presented as the average ± SD of three
independent experiments, each run in duplicate. (C) Dose−response
data (EC50) for all stereoisomers in the GFP-LC3 punctae formation
assay. Values are presented as average ± SEM. (D) Representative
images from the GFP-LC3 punctae formation assay following
treatment with DMSO; PI-103 (5 μM); BRD1240 and its enantiomer,
BRD4849 (RRR); and BRD8705 (RSS) and its enantiomer, BRD2595
(SRR) (all 20 μM). Blue (Hoechst 33342), green (eGFP). Scalar bars
represent 10 μm.
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dependent on the three-dimensional structure of the molecule.
Notably, the enantiomer of BRD1240 (BRD4849), which has
the same physicochemical properties as BRD1240, does not
cause an increase in GFP-LC3 punctae number, supporting a
hypothesis that BRD1240 does not simply perturb lysosomal
function by accumulating nonspeciﬁcally within the organelle as
has been observed for other small molecules.23
The number of GFP-LC3 punctae in the cell can be
increased by either activation of autophagy or inhibition of
autophagy at a late step in the process, such as by disrupting
lysosomal function. To test BRD1240 for these activities, we
performed an assay for autophagosome formation and
maturation (ﬂux) that relies on visualizing an LC3 protein
tagged with both mCherry and eGFP. The assay exploits the
diﬀerential sensitivities of mCherry and eGFP to the acidic
lysosomal environment to infer autophagic ﬂux. The eGFP
signal is attenuated in autolysosomes, while the mCherry signal
remains stable;32 as a result, autophagosomes (eGFP+/
mCherry+: yellow puncta) and autolysosomes (eGFP−/
mCherry+: red puncta) can be distinguished and counted by
high-throughput imaging. This assay was optimized using a
known activator of autophagy, PI-103 (dual inhibitor of mTOR
and PI3K), and a known inhibitor of lysosomal acidiﬁcation,
baﬁlomycin A1 (V-ATPase inhibitor). As expected, PI-103
robustly increased the number of autolysosomes (red puncta),
while baﬁlomycin A1 (BafA1) increased the number of
autophagosomes (yellow puncta) by blocking autophagic ﬂux
(Figure 2A). Similar to BafA1, BRD1240 and its active
diastereomer (BRD8705) robustly inhibited autolysosome
formation, causing a signiﬁcant accumulation of autophago-
somes (Figure 2A). These results suggest that BRD1240 blocks
autophagosomal turnover. In further support of this hypothesis,
we found that treatment with BRD1240, when cotreated with
the lysosomal protease inhibitors, E64d and pepstatin A
(pepA), caused no additional increase in LC3-II/LC3-I ratio
by Western blot (Figure 2B).
BRD1240 Modulates Lysosomal Function. To deter-
mine whether BRD1240 disrupts autophagic ﬂux by perturbing
lysosomal function, we ﬁrst tested its eﬀects on cellular staining
with a pH-sensitive cationic ﬂuorescent dye (LysoTracker Red)
which accumulates in acidic cellular compartments.33 The
ﬂuorescent signal was greatly diminished after BRD1240 and
BRD8705 treatment, suggesting that the compounds may
inhibit lysosomal acidiﬁcation (Figure 2C, Supporting
Information Figure S2B). In contrast, none of the inactive
stereoisomers was capable of diminishing the ﬂuorescent
LysoTracker signal. We then tested whether BRD1240 aﬀected
the ability of lysosomal proteases, which require an acidic
environment for optimal activity, to process a ﬂuorogenic
substrate (DQ-BSA).34 As expected, treatment with com-
pounds that inhibit lysosomal proteases directly (E64d/pepA)
or indirectly by increasing lysosomal pH (BafA1 and
chloroquine) signiﬁcantly decreased both DQ-BSA punctae
number and intensity (Figure 2D, Supporting Information
Figure S2C). We found that treatment with BRD1240 and
BRD8705 for 6 h also robustly decreased DQ-BSA punctae
number and intensity, whereas the inactive stereoisomers had
no activity in the assay. These data implicate the lysosome as a
potential site of action of BRD1240.
Figure 2. BRD1240 blocks the later stages of autophagy. (A) Representative images from the mCherry-eGFP-LC3 assay following treatment with
DMSO, PI-103 (5 μM), BafA1 (100 nM), BRD1240 (10 μM), BRD8705 (10 μM), and BRD4849 (10 μM). Blue (Hoechst 33342), red (mCherry),
green (eGFP). Scalar bars represent 10 μm. (B) Western blot for LC3-I to LC3-II shift in HeLa cells treated with BafA1, BRD1240, and BRD4849 ±
10 μg/mL E64d/pepA. (C) Normalized average ﬂuorescence intensity of punctae per cell for BafA1 (100 nM), BRD1240 (SSS) (10 μM), and all
seven stereoisomers (10 μM) in HeLa cells in the LysoTracker displacement assay. (D) Normalized average punctae number per cell for BafA1 (200
nM), chloroquine (CQ) (50 μM), E64d/pepA (10 μg/mL), BRD1240 (20 μM), and all seven stereoisomers (20 μM) in HeLa cells in the DQ-BSA
assay. In parts C and D data are presented as the average ± SD of three independent experiments, each run in duplicate.
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BRD1240 Has Notable Structure−Activity Relation-
ships. To understand better the structural elements that, in
addition to the stereochemistry of the ring, are required for the
activity of BRD1240, we tested analogues of BRD1240 in both
the GFP-LC3 and LysoTracker assays (Table 1 and Supporting
Information Table S1). Movement of the nitrogen of the
pyridine from the 4-position to the 3-position, or replacement
of the pyridine with a phenyl ring, resulted in a complete loss of
activity, conﬁrming the importance of the nitrogen heteroatom
at this position. It is possible that this nitrogen participates in a
critical hydrogen bonding interaction with a protein target of
BRD1240. Changes to the urea moiety were slightly more
tolerated. Complete removal of the piperonyl urea ablated
activity as did replacement of the urea with various amides;
however, exchange of the piperonyl urea moiety with a meta-
methoxy urea moiety yielded an active analogue. These
observations suggest that an electron-rich phenyl urea is
optimal for activity, but subtle changes at this position may be
acceptable. More drastic changes to either position resulted in
completely inactive analogues. Importantly, the SAR trends
observed in the GFP-LC3 assay are paralleled in the
LysoTracker assay, strengthening the hypothesis that
BRD1240’s eﬀects on autophagosome number are linked to
its ability to perturb lysosomal function.
BRD1240 Kills a Similar Subset of Cancer Cells as the
V-ATPase Inhibitor, Baﬁlomycin A1. Proﬁling the sensitivity
of cancer cell lines to small molecules has emerged as a
powerful tool for gaining insights into their mechanisms of
action.35 Compounds with similar mechanisms of action have
been shown to elicit a similar pattern of responses across panels
of cancer cell lines.35−37 We measured the sensitivity of 83
cancer cell lines to BRD1240 and its inactive enantiomer,
BRD4849, and compared it to the patterns of sensitivity
measured for 479 other small molecules spanning a diverse
range of known mechanisms of action gathered as part of the
NCI’s Cancer Target Discovery and Development Network.38
We found that the patterns of sensitivity elicited by BRD1240
and BafA1 were highly similar, while such correlation was not
observed between the inactive stereoisomer BRD4849 and
BafA1 (Figure 3B,C). Furthermore, among the 481 compounds
tested in these 83 cancer cell lines in the project, the correlation
between BRD1240 and BafA1 is the strongest (Figure 3D).
These data suggest that BRD1240 and BafA1 may share a
common mechanism of action, and that BRD1240 may inhibit
lysosomal acidiﬁcation by directly suppressing the activity of V-
ATPase.
BRD1240 Suppresses V-ATPase Function in Biochem-
ical Assays Using Membrane Fractions. To determine
whether BRD1240 perturbs lysosomal acidiﬁcation by modu-
lating V-ATPase activity, we tested its activity in a previously
Table 1. BRD1240 Analogues Reveal Structure−Activity
Relationships in GFP-LC3a and LysoTracker Assaysb
aGFP-LC3 punctae formation data are presented as the average of
three independent experiments run in duplicate and are reported as
relative average % intensity ± SEM at 20 μM. bLysoTracker
displacement data are presented as the average of two independent
experiments run in duplicate and are reported as relative average %
intensity ± SEM at 20 μM. Figure 3. Comparison of 481 compounds in 83 cancer cell lines
reveals a signiﬁcant correlation between BRD1240, but not inactive
stereoisomer BRD4849, and baﬁlomycin A1, a potent V-ATPase
inhibitor. (A) Chemical structures of BRD1240 and BafA1. (B, C)
Scatter plots presenting the area under the curve (AUC) for each cell
line in response to compound treatments. r values indicate the
Spearman correlation coeﬃcient calculated on the basis of each data
plot. (D) Box and whisker plot showing the Spearman correlation
coeﬃcient between sensitivities of BRD1240 or BafA1 and the other
480 compounds tested in 83 cancer cell lines.
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described in vitro V-ATPase activity assay using cellular
membrane fractions (Figure 4A).16 Both BRD1240 and
BafA1 suppressed lysosomal acidiﬁcation in this assay.
Interestingly, the activity of BRD1240 was dependent on
pretreating the system with the compound for 1 h, while BafA1
performed identically regardless of whether a pretreatment step
was included (Figure 4B,C). Our results suggest that BRD1240
perturbs lysosomal acidiﬁcation by suppressing V-ATPase
function, but potentially by a mode of action diﬀerent than
that of BafA1. Additional work will be required to identify the
speciﬁc protein target of BRD1240, and whether this target is
among the multiple subunits of the V-ATPase complex or its
accessory regulatory factors.
■ CONCLUSION
Small-molecule probes have been critical to understanding the
dynamic and multifunctional role of the lysosome in cellular
physiology. We have identiﬁed BRD1240 as a novel small-
molecule inhibitor of lysosomal acidiﬁcation potentially
operating via suppression of V-ATPase function. BRD1240
was derived from diversity-oriented synthesis, and its activity
displays striking dependence on the stereochemistry of the ring.
It promotes cell death in numerous cancer cell lines with a
sensitivity proﬁle that correlates signiﬁcantly to that of the
naturally occurring V-ATPase inhibitor, baﬁlomycin A1. These
results highlight the power of DOS and HTS to yield novel,
potent, and selective probes to study cellular pathways of
biological and medical interest.
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